Boston Scientific Corporation (ETR:BSX)
Germany · Delayed Price · Currency is EUR | Market Cap | 116.75B -15.9% |
| Revenue (ttm) | 16.49B +21.6% |
| Net Income | 2.38B +55.7% |
| EPS | 1.59 +54.7% |
| Shares Out | n/a |
| PE Ratio | 49.08 |
| Forward PE | 27.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 80 |
| Average Volume | 510 |
| Open | 79.20 |
| Previous Close | 78.80 |
| Day's Range | 77.40 - 79.20 |
| 52-Week Range | 74.60 - 104.00 |
| Beta | n/a |
| RSI | 42.46 |
| Earnings Date | Feb 4, 2026 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]
Financial Performance
In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.
Financial numbers in USD Financial StatementsNews
Artisan Global Opportunities Fund Q4 2025 Portfolio Update
Among our top contributors in Q4 were Argenx, Lam Research and Insmed. Among our biggest detractors in Q4 were Oracle, Netflix and BAE Systems. During the quarter, we initiated new positions in RTX (R...
Calls of the Day: Wynn, Cummins, Boston Scientific, Applovin and Monster Beverage
The Investment Committee debate the latest Calls of the Day.
Goldman Sachs Strategic Factor Allocation Fund Buys 25,122 Shares of Boston Scientific Corp (BSX)
Goldman Sachs Strategic Factor Allocation Fund Buys 25,122 Shares of Boston Scientific Corp (BSX)
Franklin U.S. Large Cap Equity Fund Sells 11,613 Shares of Boston Scientific Corp (BSX)
Franklin U.S. Large Cap Equity Fund Sells 11,613 Shares of Boston Scientific Corp (BSX)
Voya Large-Cap Growth Fund Sells 54,455 Shares of Boston Scientific Corp (BSX)
Voya Large-Cap Growth Fund Sells 54,455 Shares of Boston Scientific Corp (BSX)
Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock.
What Does the Market Think About Boston Scientific Corp?
Boston Scientific Corp's (NYSE: BSX) short interest as a percent of float has risen 4.62% since its last report. According to exchange reported data, there are now 20.01 million shares sold short , w...
RICHARDSON FINANCIAL SERVICES INC. Buys 141 Shares of Boston Scientific Corp (BSX)
RICHARDSON FINANCIAL SERVICES INC. Buys 141 Shares of Boston Scientific Corp (BSX)
A Closer Look at Boston Scientific's Options Market Dynamics
Financial giants have made a conspicuous bullish move on Boston Scientific. Our analysis of options history for Boston Scientific (NYSE: BSX) revealed 21 unusual trades. Delving into the details, we ...
Weaver Capital Management LLC Sells 119 Shares of Boston Scientific Corp (BSX)
Weaver Capital Management LLC Sells 119 Shares of Boston Scientific Corp (BSX)
Polen Global Growth Portfolio Q4 2025 Performance, Attribution & Portfolio Activity
In Q4 2025, Polen Capital initiated a new position in Tencent Holdings and Spotify and sold its positions in Sage Group, Willis Towers Watson, ICON Plc, and Workday. Eli Lilly was the top performing r...
Boston Scientific Advises Removal Of Certain AXIOS Stents After Deployment Issues Surface
The U.S. Food and Drug Administration (FDA) said it is aware that Boston Scientific Corporation (NYSE: BSX) has alerted customers to remove certain AXIOS stents and electrocautery-enhanced delivery s...
J&J's Guidance Wallops Views, But Boston Scientific, Medtronic Take A Toll
Johnson & Johnson stock fell Wednesday despite a fourth-quarter beat as Medtronic and Boston Scientific continued gaining share in PFA.
Independence Bank of Kentucky Buys 1,007 Shares of Boston Scientific Corp (BSX)
Independence Bank of Kentucky Buys 1,007 Shares of Boston Scientific Corp (BSX)
GraniteShares Advisors LLC Sells 12,112 Shares of Boston Scientific Corp (BSX)
GraniteShares Advisors LLC Sells 12,112 Shares of Boston Scientific Corp (BSX)
Revolve Wealth Partners, LLC Sells 2,126 Shares of Boston Scientific Corp (BSX)
Revolve Wealth Partners, LLC Sells 2,126 Shares of Boston Scientific Corp (BSX)
$100 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today
Boston Scientific (NYSE: BSX) has outperformed the market over the past 10 years by 4.48% on an annualized basis producing an average annual return of 18.03%. Currently, Boston Scientific has a marke...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
BALA CYNWYD, Pa., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
HARBOR CAPITAL ADVISORS, INC. Sells 31 Shares of Boston Scientific Corp (BSX)
HARBOR CAPITAL ADVISORS, INC. Sells 31 Shares of Boston Scientific Corp (BSX)
TOTH FINANCIAL ADVISORY CORP Buys 67 Shares of Boston Scientific Corp (BSX)
TOTH FINANCIAL ADVISORY CORP Buys 67 Shares of Boston Scientific Corp (BSX)
Marquette Asset Management, LLC Sells 204 Shares of Boston Scientific Corp (BSX)
Marquette Asset Management, LLC Sells 204 Shares of Boston Scientific Corp (BSX)
MRA Advisory Group Sells 2,547 Shares of Boston Scientific Corp (BSX)
MRA Advisory Group Sells 2,547 Shares of Boston Scientific Corp (BSX)
Notable healthcare headlines for the week: Eli Lilly, UnitedHealth, and Boston Scientific in focus
Wall Street healthcare weekly recap: UNH Medicare probe, Lilly-Nvidia AI drug lab, BSX-Penumbra deal, AbbVie pricing pact, plus top XLV movers—read now.
Key deals this week: Micron Technology, Worthington Steel, Boston Scientific, CrowdStrike and more
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN
NEW YORK and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.